GlassScriptPhysician profile
Michael John Lazar
NPI 1962469650
$8,160.50
in general payments reported to CMS, 2019-2025
19 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,410 · 2020: $561 · 2021: $781 · 2022: $984 · 2023: $1,532 · 2024: $1,555 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $3,572.08 | 2019-2025 | Synergy Ablation System |
| Intuitive Surgical, INC. | $2,820.88 | 2019-2024 | Da Vinci Surgical System |
| Medtronic Vascular, INC. | $275.40 | 2019-2020 | |
| Medistim USA, INC. | $157.11 | 2020-2024 | Miraq |
| Novus Surgical Consultants | $154.04 | 2023 | |
| Baxter Healthcare | $140.18 | 2020-2024 | Preveleak |
| Arthrex, INC. | $137.94 | 2023 | Shoulder Implants |
| Abiomed | $135.39 | 2024 | Impella |
| Ethicon US, LLC | $121.68 | 2025 | Prolene, Evarrest |
| Astrazeneca Pharmaceuticals LP | $119.70 | 2023 | Farxiga |
| Abbvie INC. | $104.30 | 2024 | |
| Abbott Laboratories | $95.33 | 2020 | |
| Getinge USA Sales, LLC | $85.20 | 2025 | Vasoview Hemopro 2 |
| Cerus Corporation | $77.78 | 2024 | Intercept Blood System For Platelets |
| Janssen Pharmaceuticals, INC | $57.82 | 2023-2024 | Xarelto |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $37.12 | 2024-2025 | |
| Medtronic, INC. | $30.83 | 2022 | |
| Angiodynamics, INC. | $22.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.